机构：[1]Jilin Canc Hosp, Internal Med, Changchun, Peoples R China[2]Mianyang Cent Hosp, Oncol, Mianyang, Sichuan, Peoples R China[3]Zhejiang Univ, Sir Run Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China[4]Beijing Canc Hosp, Dept Hepatopancreatobiliary Surg 2, Beijing, Peoples R China[5]Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China[6]Hebei Med Univ, Med Oncol, Hosp 4, Shijiazhuang, Hebei, Peoples R China临床科室肿瘤内科河北医科大学第四医院[7]Zhejiang Prov Peoples Hosp, Med Oncol, Hangzhou, Peoples R China[8]Bengbu Med Coll, Med Oncol, Affiliated Hosp 1, Bengbu, Peoples R China[9]Shandong Simcere Biopharmaceut Co Ltd, Clin Sci, Shandong, Peoples R China[10]Shandong Simcere Biopharmaceut Co Ltd, Clin Pharmacol, Nanjing, Peoples R China[11]Shandong Simcere Biopharmaceut Co Ltd, Clin Stat, Yantai, Peoples R China
第一作者机构：[1]Jilin Canc Hosp, Internal Med, Changchun, Peoples R China
推荐引用方式(GB/T 7714)：
Ma L.,Zhang Y.,Fang Y.,et al.Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial[J].ANNALS OF ONCOLOGY.2023,34:S599-S600.doi:10.1016/j.annonc.2023.09.2105.
APA：
Ma, L.,Zhang, Y.,Fang, Y.,Hao, C.,Fan, Q....&Cheng, Y..(2023).Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial.ANNALS OF ONCOLOGY,34,
MLA：
Ma, L.,et al."Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial".ANNALS OF ONCOLOGY 34.(2023):S599-S600
医学